Articles in IPOs

Renaissance Capital

Cardiovascular diagnostics company Lantheus Holdings postpones IPO

Lantheus Holdings, which sells medical imaging agents used in the diagnosis of cardiovascular diseases, postponed its IPO on Wednesday, citing poor market conditions. The North Billerica, MA... Read >>

Renaissance Capital

Bio Blast Pharma prices IPO at $11, the low end of the range

Bio Blast Pharma, a biotech developing treatments for rare and ultra rare genetic diseases, raised $35 million by offering 3.2 million shares at $11, the low end of the range of $11 to $13. Bio... Read >>

Renaissance Capital

Vascular Biogenics prices IPO at $12, below the range

Vascular Biogenics, which is developing gene therapies for cancer and small molecules for inflammation, raised $65 million by offering 5.4 million shares at $12, below the range of $13 to $15.... Read >>

Renaissance Capital

HealthEquity prices IPO at $14, above the range

HealthEquity, which offers an integrated platform for managing Health Savings Accounts (HSAs), raised $127 million by offering 9.1 million shares at $14, above its $10 to $12 range. HealthEquity... Read >>

Renaissance Capital

Avalanche Biotechnologies prices upsized IPO at $17, the high end of the upwardly revised range

Avalanche Biotechnologies, an early stage biotech developing a gene therapy for wet AMD, raised $102 million by offering 6.0 million shares at $17, the high end of its upwardly revised $16 to... Read >>

Renaissance Capital

Catalent prices IPO at $20.50, midpoint of the range

Catalent, a global provider of oral, injectable and respiratory drug delivery technologies, raised $871 million by offering 42.5 million shares (100% primary) at $20.50, the midpoint of the $19... Read >>

Renaissance Capital

Macrocure prices IPO well below the range at $10

Macrocure, an Israeli biotech developing white blood cell injections to treat hard to heal wounds, raised $54 million by offering 5.4 million shares (all primary) at $10, well below the range of... Read >>

Renaissance Capital

Synchrony Financial prices IPO at $23, low end of the range

Synchrony Financial, a spinoff of GE's private label credit card and consumer finance business, raised $2.9 billion by offering 125 million shares at $23, the low end of the range of $23 $26.... Read >>

Renaissance Capital

IPOs back from bankruptcy

The IPO market will see two weeks in a row with an initial public offering from a company taken out of bankruptcy in a PE buyout. Last week, radio station operator Townsquare Media ( TSQ )... Read >>

Renaissance Capital

Biotech EyeGate Pharmaceuticals files for a $29 million IPO

EyeGate Pharmaceuticals, a late stage biotech developing a therapy for eye inflammation, filed on Wednesday with the SEC to raise up to $29 million in an initial public offering. The company has... Read >>

Displaying 71-80 of 2608
<< first 8 9 10 11 12 50 100 150 200 250 last >>